Literature DB >> 21359507

The burden of illness of rheumatoid arthritis.

Annelies Boonen1, Johan L Severens.   

Abstract

It is necessary to understand the full burden of illness of a disease before the value of interventions can be assessed. Rheumatoid arthritis (RA) has an impact on a variety of stakeholders, including patients, healthcare systems, and society as a whole. This overview discusses the societal and patient perspectives, distinguishing several domains of impact. Epidemiology is important from a societal perspective, as it affects the total impact on health and costs related to RA and influences healthcare organization priorities. Co-morbidities, such as cardiovascular disease, are important factors contributing to the impact of RA. The impact on health is, naturally, relevant to both patients and society as a whole, and is summarized by health-related quality-of-life measures from the point of view of the patient and by utilities from the societal perspective. Similarly, work participation is important for both patients and society. Withdrawal from the labor force and short- and long-term sick leave are extensively studied in RA and lead to substantial productivity costs at the societal level and to income loss for patients. In addition, the recent concept of presenteeism, which reflects the problems that patients experience while at work, is considered. Finally, the costs of illness of RA are summarized. Societal costs are mainly driven by the costs of drug treatment and inpatient care, including surgery. Patient and family costs are mainly driven by the need for formal and informal care. Overall, RA has a significant impact on the health of and costs to patients and society, suggesting that effective interventions to reduce the impact are of value.

Entities:  

Mesh:

Year:  2011        PMID: 21359507     DOI: 10.1007/s10067-010-1634-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

Review 1.  Overview of work disability in rheumatoid arthritis patients as observed in cross-sectional and longitudinal surveys.

Authors:  S M M Verstappen; J W J Bijlsma; H Verkleij; E Buskens; A A M Blaauw; E J ter Borg; J W G Jacobs
Journal:  Arthritis Rheum       Date:  2004-06-15

2.  Employment across chronic inflammatory rheumatic diseases and comparison with the general population.

Authors:  Wilfried Mau; Joachim Listing; Doerte Huscher; Henning Zeidler; Angela Zink
Journal:  J Rheumatol       Date:  2005-04       Impact factor: 4.666

Review 3.  Health state utility values: a description of their development and application for rheumatic diseases.

Authors:  Nick Bansback; Mark Harrison; John Brazier; Linda Davies; Jacek Kopec; Carlo Marra; Deborah Symmons; Aslam Anis
Journal:  Arthritis Rheum       Date:  2008-07-15

4.  A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis.

Authors:  Carlo A Marra; John C Woolcott; Jacek A Kopec; Kamran Shojania; Robert Offer; John E Brazier; John M Esdaile; Aslam H Anis
Journal:  Soc Sci Med       Date:  2005-04       Impact factor: 4.634

Review 5.  Consequences of rheumatoid arthritis for performance of social roles--a literature review.

Authors:  Goedele A Geuskens; Alex Burdorf; Johanna M W Hazes
Journal:  J Rheumatol       Date:  2007-04-01       Impact factor: 4.666

6.  Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US.

Authors:  C P Chung; T Sokka; P G Arbogast; T Pincus
Journal:  Ann Rheum Dis       Date:  2006-06-01       Impact factor: 19.103

7.  Healthcare consumption and direct costs of rheumatoid arthritis in Belgium.

Authors:  R Westhovens; A Boonen; L Verbruggen; P Durez; L De Clerck; M Malaise; H Mielants
Journal:  Clin Rheumatol       Date:  2005-05-14       Impact factor: 2.980

8.  Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?

Authors:  S Curkendall; V Patel; M Gleeson; R S Campbell; M Zagari; R Dubois
Journal:  Arthritis Rheum       Date:  2008-10-15

9.  Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis.

Authors:  Wei Zhang; Nick Bansback; Daphne Guh; Xin Li; Bohdan Nosyk; Carlo A Marra; Aslam H Anis
Journal:  J Rheumatol       Date:  2008-08-01       Impact factor: 4.666

10.  Development of a work instability scale for rheumatoid arthritis.

Authors:  Gill Gilworth; M Anne Chamberlain; Andrew Harvey; Amanda Woodhouse; Jacqui Smith; M Glyn Smyth; Alan Tennant
Journal:  Arthritis Rheum       Date:  2003-06-15
View more
  37 in total

1.  The burden of disease in rheumatoid arthritis.

Authors:  Till Uhlig; Rikke H Moe; Tore K Kvien
Journal:  Pharmacoeconomics       Date:  2014-09       Impact factor: 4.981

Review 2.  Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries.

Authors:  Márta Péntek; Gyula Poór; Piotr Wiland; Martina Olejárová; Marek Brzosko; Catalin Codreanu; Nóra Brodszky; László Gulácsi
Journal:  Eur J Health Econ       Date:  2014-05-16

3.  Rheumatoid arthritis - an update for general dental practitioners.

Authors:  S de Souza; R K Bansal; J Galloway
Journal:  Br Dent J       Date:  2016-11-18       Impact factor: 1.626

4.  Barriers to accessing biologic treatment for rheumatoid arthritis in Greece: the unseen impact of the fiscal crisis--the Health Outcomes Patient Environment (HOPE) study.

Authors:  Kyriakos Souliotis; Manto Papageorgiou; Anastasia Politi; Dimitrios Ioakeimidis; Prodromos Sidiropoulos
Journal:  Rheumatol Int       Date:  2013-09-22       Impact factor: 2.631

5.  Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.

Authors:  C Tzanetakos; A Tzioufas; A Goules; G Kourlaba; T Theodoratou; P Christou; N Maniadakis
Journal:  Rheumatol Int       Date:  2017-05-18       Impact factor: 2.631

6.  [Do we still need clinical studies in rheumatology?].

Authors:  U Henkemeier; R Alten; B Bannert; X Baraliakos; F Behrens; F Heldmann; U Kiltz; M Köhm; R König; J Leipe; U Müller-Ladner; J Rech; E Riechers; A Rubbert-Roth; R E Schmidt; H Schulze-Koops; C Specker; A-K Tausche; S Wassenberg; M Witt; T Witte; J Zernicke; H Burkhardt
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

7.  Sociodemographic Determinants of Out-of-Pocket Expenditures for Patients Using Prescription Drugs for Rheumatoid Arthritis.

Authors:  Kumar Mukherjee; Khalid M Kamal
Journal:  Am Health Drug Benefits       Date:  2017-02

8.  Sense of coherence and self-sacrificing defense style as predictors of psychological distress and quality of life in rheumatoid arthritis: a 5-year prospective study.

Authors:  Panagiota Goulia; Paraskevi V Voulgari; Niki Tsifetaki; Elias Andreoulakis; Alexandros A Drosos; André F Carvalho; Thomas Hyphantis
Journal:  Rheumatol Int       Date:  2014-09-21       Impact factor: 2.631

Review 9.  The importance of rheumatology biologic registries in Latin America.

Authors:  Maria de la Vega; Hellen M da Silveira de Carvalho; Lucio Ventura Ríos; Maria V Goycochea Robles; Gustavo C Casado
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

10.  Burden for Parents of Patients With Schizophrenia-A Nationwide Comparative Study of Parents of Offspring With Rheumatoid Arthritis, Multiple Sclerosis, Epilepsy, and Healthy Controls.

Authors:  Ellenor Mittendorfer-Rutz; Syed Rahman; Antti Tanskanen; Maila Majak; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Heidi Taipale; Jari Tiihonen
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.